Several home-produced substances such as krokodil and boltushka are prevalent in many Eastern European countries. Anecdotal reports of its use have been circulating in Germany and Norway; however, this has not been confirmed. Its use has also been reported by the media in the USA, although only one confirmed report of its use exists. Home-produced drugs are associated with high levels of morbidity and a number of complex health issues such as the spread of blood borne viruses, gangrene, and internal organ damage. The high incidence of HIV rates amongst people who inject home-produced substances is a public health concern. The resulting physical health consequences of injecting these crude substances are very severe in comparison to heroin or amphetamine acquired in black markets. Due to this fact and the increased mortality associated with these substances, professionals in the area of prevention, treatment, and policy development need to be cognisant of the presentation, harms, and the dangers associated with home-produced substances globally. This scoping review aimed to examine existing literature on the subject of home-produced heroin and amphetamine-type stimulant substitutes. The review discussed the many implications such research may have in the areas of policy and practice. Data were gathered through the use of qualitative secondary resources such as journal articles, reports, reviews, case studies, and media reports. The home production of these substances relies on the utilisation of precursor drugs such as less potent stimulants, tranquillizers, analgesics, and sedatives or natural plant ingredients. The Internet underpins the facilitation of this practice as recipes, and diverted pharmaceutical sales are available widely online, and currently, ease of access to the Internet is evident worldwide. This review highlights the necessity of prevention, education, and also harm reduction related to home-produced drugs and also recommends consistent monitoring of online drug fora, online drug marketplaces, and unregulated pharmacies.

Centre for Public Health Liverpool John Moores University Liverpool UK

CVO Addiction Research Centre Utrecht The Netherlands

Department of Addictology 1st Faculty of Medicine Charles University Prague Czech Republic

Freudenthal Institute for Science and Mathematics Education Utrecht University Utrecht The Netherlands

School of Health Sciences Waterford Institute of Technology Waterford Ireland

Zobrazit více v PubMed

Grund JPC, Zábranský T, Irwin K, Heimer R. Stimulant use in Central and Eastern Europe: how recent social history shaped current drug consumption patterns. In: Pates R, Riley D, editors. Interventions for amphetamine misuse. Oxford: Wiley-Blackwell; 2009. pp. 173–204.

Grund JPC. A Candle lit from both sides: the epidemic of HIV infection in Central and Eastern Europe. In: McElrath K, editor. HIV and AIDS: A global view. Westport, CT: Greenwood Press; 2002. pp. 41–68.

Heimer R, Booth RE, Irwin KS, Merson MH. HIV and drug use in Eurasia. In: Twigg JL, editor. HIV/AIDS in Russia and Eurasia. Volume 2. Basingstoke, Hampshire, UK: Palgrave Macmillan; 2007.

Orlova AV. The Russian “war on drugs”: a kinder, gentler approach? Probl Post Communism. 2009;56(Suppl. 1):23–34. doi: 10.2753/PPC1075-8216560103. DOI

Dehne KL, Grund JPC, Khodakevich L, Kobyshcha Y. The HIV/AIDS epidemic among drug injectors in Eastern Europe: patterns, trends and determinants. J Drug Issues. 1999;29(Suppl. 4):729–76. doi: 10.1177/002204269902900402. DOI

Rhodes T, Ball A, Stimson GV, Kobyshcha Y, Fitch C, Pokrovsky V, et al. HIV infection associated with drug injecting in the Newly Independent States, Eastern Europe: the social and economic context of epidemics. Addiction. 1999;94(9):1323–36. PubMed

Barnett T, Whiteside A, Khodakevich L, Kruglov Y, Steshenko V. The HIV/AIDS epidemic in Ukraine: its potential social and economic impact. Soc Sci Med. 2000;51(Suppl. 9):1387–403. doi: 10.1016/S0277-9536(00)00104-0. PubMed DOI

Des Jarlais DC, Grund J-PC, Zadoretzky C, Milliken J, Friedmann P, Titus S, et al. HIV risk behaviour among participants of syringe exchange programmes in central/eastern Europe and Russia. Int J Drug Policy. 2002;13:165–74.

Balakireva OM, Grund J-PC, Barendregt C, Rubanets YV, Ryabova MV, Volyk AM, Levchuk N, Meshcherina O, Bondar T. Risk and protective factors in the initiation of injecting drug use: report of a respondent driven sampling study and strategy paper on preventing the initiation of injecting drug use among vulnerable adolescents and young people. Kiev: UNICEF/UISR. [http://www.unicef.org/ukraine/3_HIV_injecting_drug_users_en.pdf]. Accessed 18 Mar 2013.

Booth RE, Lehman WEK, Latkin CA, Dvoryak S, Brewster JT, Royer MS, et al. Individual and network interventions with injection drug users in 5 Ukraine cities. Am J Public Health. 2011;101 Suppl 2:336–43. PubMed PMC

Alcabes P, Grund JPC, Beniowski M, Bozek B, Kaciuba A, Zielinski A. Possible epidemic spread of HIV by syringe-based drug sharing in Poland: paradigm for the new AIDS frontier: 28 June - 3 July 1998. Geneva: 12th World AIDS Conference; 1998.

Latypov AB. The Soviet doctor and the treatment of drug addiction: “a difficult and most ungracious task”. Harm Reduct J. 2011;8:32. doi: 10.1186/1477-7517-8-32. PubMed DOI PMC

Cone EJ. Ephemeral profiles of prescription drug and formulation tampering: evolving pseudoscience on the Internet. Drug Alcohol Depend. 2006;83(Suppl. 1):31–9. doi: 10.1016/j.drugalcdep.2005.11.027. PubMed DOI

Grund JPC, Latypov AB, Harris M. Breaking worse: the emergence of krokodil and excessive injuries among people who inject drugs in Eurasia. Int J Drug Policy. 2013;24(Suppl. 4):265–74. doi: 10.1016/j.drugpo.2013.04.007. PubMed DOI

Brandt SD, King LA, Evans-Brown M. The new drug phenomenon. Drug Test Anal. 2014;6(Suppl. 7–8):587–97. doi: 10.1002/dta.1686. PubMed DOI

Van Hout MC. Kitchen chemistry: a scoping review of the diversionary use of pharmaceuticals for non-medicinal use and home production of drug solutions. Drug Test Anal. 2014;6(Suppl. 7–8):778–87. doi: 10.1002/dta.1622. PubMed DOI

UNODC . World drug report 2013. Vienna: United Nations; 2013.

Azbel L, Dvoryak S, Altice FL. ‘Krokodil’ and what a long strange trip it’s been. Int J Drug Policy. 2013;24(Suppl. 4):275–80. PubMed PMC

Gahr M, Freudenmann RW, Hiemke C, Gunst IM, Connemann BJ, Schonfeldt-Lecuona C. “Krokodil”: revival of an old drug with new problems. Subst Use Misuse. 2012;47(Suppl. 7):861–3. doi: 10.3109/10826084.2012.669807. PubMed DOI

Gahr M, Freudenmann RW, Hiemke C, Gunst IM, Connemann BJ, Schonfeldt-Lecuona C. Desomorphine goes “crocodile”. J Addict Dis. 2012;31(Suppl. 4):407–12. doi: 10.1080/10550887.2012.735570. PubMed DOI

Thekkemuriyi DV, John SG, Pilai U. “Krokodil” —a designer drug from across the Atlantic, with serious consequences. Am J Med. 2014;127(Suppl. 3):1–2. doi: 10.1016/j.amjmed.2013.09.030. PubMed DOI

Zheluk A, Quinn C, Meylakhs P. Internet search and krokodil in the Russian federation: an infoveillance study. J Med Internet Res. 2014;16(Suppl. 9) doi: 10.2196/jmir.3203. PubMed DOI PMC

Alves EA, Grund JPC, Afonso CM, Netto AD, Carvalho F, Dinis-Oliveira RJ. The harmful chemistry behind krokodil (desomorphine) synthesis and mechanisms of toxicity. Forensic Sci Int. 2015;249:207–13. doi: 10.1016/j.forsciint.2015.02.001. PubMed DOI

Vearrier D, Greenberg MI, Ney Miller S, Okaneku JT, Haggerty DA. Methamphetamine: history, pathophysiology, adverse health effects, current trends, and hazards associated with the clandestine manufacture of methamphetamine. Dis Mon. 2012;28(Suppl. 2):38–89. doi: 10.1016/j.disamonth.2011.09.004. PubMed DOI

Vernon A. Response to “one-pot” meth labs. Fire Eng. 2013;166(Suppl. 11):79–82.

UNODC . World drug report 2012. Vienna: United Nations Publication; 2012.

Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Meth. 2005;8(Suppl. 1):19–32. doi: 10.1080/1364557032000119616. DOI

Levac D, Colquhoun H, O’Brien KK. Scoping studies: advancing the methodology. Implement Sci. 2010;5(Suppl. 1):69–78. doi: 10.1186/1748-5908-5-69. PubMed DOI PMC

Daudt HM, van Mossel C, Scott S. Enhancing the scoping study methodology: a large, inter-professional team’s experience with Arksey and O’Malley’s framework. BMC Med Res Methodol. 2013;13:48. doi: 10.1186/1471-2288-13-48. PubMed DOI PMC

Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States 1988 through 1994. N Engl J Med. 1999;341 Suppl 8:556–62. PubMed

Hser YI, Hoffman V, Grella CE, Anglin MD. A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry. 2001;58(Suppl. 5):503–8. doi: 10.1001/archpsyc.58.5.503. PubMed DOI

Hser YI, Gelberg L, Hoffman V, Grella CE, McCarthy W, Anglin MD. Health conditions among aging narcotics addicts: medical examination results. J Behav Med. 2004;27(Suppl. 6):607–22. doi: 10.1007/s10865-004-0005-x. PubMed DOI

Hser YI, Huang D. Trajectories of heroin addiction: growth mixture modelling results based on a 33-year follow-up study. Evaluation Rev. 2007;31(Suppl. 6):548–63. doi: 10.1177/0193841X07307315. PubMed DOI

UNODC . World drug report 2010. Vienna: United Nations Publication; 2010.

Hutchings HA, Eccles R. The opioid agonist codeine and antagonist naltrexone do not affect voluntary suppression of capsaicin induced cough in healthy subjects. Eur Res J. 1994;7(Suppl. 4):715–9. doi: 10.1183/09031936.94.07040715. PubMed DOI

Bhandari M, Bhandari A, Bhandari A. Recent updates on codeine. Pharm Methods. 2011;2(Suppl. 1):3–8. doi: 10.4103/2229-4708.81082. PubMed DOI PMC

Hou H, Yin S, Jia S, Hu S, Sun T, Chen Q, et al. Decreased striatal dopamine transporters in codeine-containing cough syrup abusers. Drug Alcohol Depend. 2011;118(Suppl 2–3):148–51. PubMed

Vree TB, van Dongen RT, Koopman-Kimenai PM. Codeine analgesia is due to codeine-6-glucuronide, not morphine. Int J Clin Pract. 2000;54(Suppl. 6):395–8. PubMed

Shek DT, Lam CM. Adolescent cough medicine abuse in Hong Kong: implications for the design of positive youth development programs in Hong Kong. Int J Adolesc Med Health. 2006;18(Suppl. 3):493–503. PubMed

Yang Y, Yuan QY. Investigation and analysis on personalities of male-codeine phosphate addicts by MMPI. Chinese J Drug Abuse Prevent Treat. 2008;14:143–5.

Reed K, Bond A, Witton J, Cornish R, Hickman M, Strang J. The changing use of prescribed benzodiazepines and z-drugs and of over-the-counter codeine-containing products in England: a structured review of published english and international evidence and available data to inform consideration of the extent of dependence and harm. London: The National Addiction Centre, Kings College London; 2011

Van Hout MC. Nod and wave: an Internet study of the codeine intoxication phenomenon. Int J Drug Policy. 2015;26(Suppl. 1):67–77. doi: 10.1016/j.drugpo.2014.06.016. PubMed DOI

World Health Organization (WHO) Disease control priorities related to mental, neurological, developmental and substance abuse disorders. Disease Control Priorities Project, Department of Mental Health and Substance Abuse. Geneva: WHO; 2006.

Chintalova-Dallas R, Case P, Kitsenko N, Lazzarine Z. Boltushka: homemade amphetamine-type stimulant and HIV risk in Odessa, Ukraine. Int J Drug Policy. 2009;20(Suppl. 4):347–51. doi: 10.1016/j.drugpo.2008.09.003. PubMed DOI PMC

Mackey S, Stewart JL, Connolly CG, Tapert SF, Paulus MP. A voxel-based morphometry study of young occasional users of amphetamine-type stimulants and cocaine. Drug Alcohol Depend. 2014;2014(135):104–11. doi: 10.1016/j.drugalcdep.2013.11.018. PubMed DOI PMC

Berman SM, Kuczenski R, McCracken JT, London ED. Potential adverse effects of amphetamine treatment on brain and behavior: a review. Mol Psychiatry. 2009;14(2):123–42. doi: 10.1038/mp.2008.90. PubMed DOI PMC

Substance Abuse and Mental Health Services Administration . Results from the 2010 national survey on drug use and health: summary of national findings. Rockville, MD: NSDUH Series H-41; 2011.

Tait RJ, McKetin R, Kay-Lambkin F, Bennett K, Tam A, Bennett A, et al. Breakingtheice: a protocol for a randomised controlled trial of an internet-based intervention addressing amphetamine-type stimulant use. BMC Psychiatry. 2012;12:67–75. PubMed PMC

Colofax G, Santos GM, Chu P, Vittinghoff E, Pluddemann A, Kumar S, et al. Amphetamine-group substances and HIV. Lancet. 2010;376(9739):458–74. PubMed

UNODC . Patterns and trends of amphetamine-type stimulants and other drugs: challenges for Asia and the Pacific. Vienna: UNODC; 2010.

Griffiths P, Mravcik V, Lopez D, Klempova D. Quite a lot of smoke but very limited fire—the use of methamphetamine in Europe. Drug Alcohol Rev. 2008;27(Suppl. 3):236–42. doi: 10.1080/09595230801932588. PubMed DOI

Booth RE. ‘Krokodil’ and other home-produced drugs for injection: a perspective from Ukraine. Int J Drug Policy. 2013;24(Suppl. 4):277–8. doi: 10.1016/j.drugpo.2013.05.009. PubMed DOI PMC

Grund JP. The eye of the needle: an ethno erpidemiological analysis of injecting drug use. In: Pates R, McBride A, Arnold K, editors. Injecting illicit drugs. Volume 8. 1. London: Blackwell; 2006.

Zábranský T. Methamphetamine in the Czech Republic. J Drug Issues. 2007;37(Suppl. 1):155–80. doi: 10.1177/002204260703700108. DOI

EMCDDA . Perspectives on drugs. Health and social responses for methamphetamine users. EMCDDA: Lisbon; 2014.

Walker S. Krokodil: the drug that eats junkies. The Independent. [http://www.independent.co.uk/news/world/europe/krokodil-the-drug-that-eats-junkies-2300787.html]. Accessed 4 Jan 2013.

Shuster S. The curse of the crocodile: Russia’s deadly designer drug. Time Magazine. [http://content.time.com/time/world/article/0,8599,2078355,00.html]. Accessed 4 Jan 2013.

Skowronek R, Celiński R, Chowaniec C. “Crocodile”—new dangerous designer drug of abuse from the East. Clin Toxicol (Phil) 2012;50(Suppl. 4):269. doi: 10.3109/15563650.2012.660574. PubMed DOI

Aretha D. Methamphetamine and amphetamines. Ernslow: Berkeley Heights, NJ; 2005.

Barcal K, Schumacher JE, Dumchev K, Moroz LV. A situational picture of HIV/AIDS and injection drug use in Vinnitsya, Ukraine. Harm Reduct J. 2005;2(Suppl. 1):16. doi: 10.1186/1477-7517-2-16. PubMed DOI PMC

Varlibas F, Delipoyraz I, Yuksel G, Filiz G, Tireli H, Gecim NO. Neurotoxicity following chronic intravenous use of “Russian cocktail”. Clin Toxicol (Phil) 2009;47(Suppl. 2):157–60. doi: 10.1080/15563650802010388. PubMed DOI

Lindblad KE. Bad news: people are taking krokodil in Norway. [http://www.vice.com/en_uk/read/krokodil-norway]. Accessed 19 Nov 2013.

Katselou M, Papoutsis I, Nikolaou P, Spiliopoulou C, Athanaselis S. A “Krokodil” emerges from the murky waters of addiction. Abuse trends of an old drug. Life Sci. 2014;102(Suppl. 2):81–7. doi: 10.1016/j.lfs.2014.03.008. PubMed DOI

Piralishvili G, Gamkrelidze I, Nikolaishvili N, Chavchanidze M. Needs assessment and treatment compliance at state opioid substitution treatment programmes in Georgia. Georgian Med News. 2013;214:8–32. PubMed

Harris M. The ‘do-it-yourself’ New Zealand injecting scene: implications for harm reduction. Int J Drug Policy. 2012;24(Suppl. 4):281–3. PubMed

Der Spiegel. Todesdroge Krokodil erreicht Deutschland. [Death drugs crocodile reaches Germany]. [http://www.spiegel.de/panorama/justiz/russischerheroinersatz-todesdroge-krokodil-erreicht-deutschland-a-791273.html]. Accessed 18 Nov 2013.

Rowlands J, Kyriakos K. Sisa: is meth use the latest face of the catastrophe in Athens? [http://www.opendemocracy.net/can-europe-make-it/joseph-rowlands-kyriakos-klosidis/sisa-is-meth-use-latest-face-of-catastrophe-in-]. Accessed 27 Mar 2014.

Miller A. Austerity’s drug of choice. Sisa is destroying the lives of Athens’s homeless people. [http://www.vice.com/en_uk/read/austeritys-drug-of-choice-000757-v20n5]. Accessed 19 Nov 2013.

Wisselink DJ, Kuijpers WGT, Mol A. Kerncijfers Verslavingszorg 2013. Landelijk Alcohol en Drugs Informatie Systeem (LADIS) Houten: Stichting IVZ; 2014.

van Gaalen S, de Bruin D, Grund J-PC. GHB overdose prevention among people who use GHB at home in the Netherlands and Belgium (2014-2015) An exploration of the characteristics associated with overdose and opportunities for risk reduction. Amsterdam: Mainline Foundation; 2015.

Booth RE, Lehman W, Kwiatkowski C, Brewster J, Sinitsyna L, Dvoryak S. Stimulant injectors in Ukraine: the next wave of the epidemic? AIDS Behav. 2008;12(Suppl. 4):652–61. doi: 10.1007/s10461-008-9359-3. PubMed DOI

Platt L, Rhodes T, Hickman M, Mikhailova L, Lisetsky K, Sarang A, et al. Changes in HIV prevalence and risk among new injecting drug users in a Russian city of high HIV prevalence. J Acquir Immune Defic Syndr. 2008;47 Suppl 5:623–31. PubMed

Zabransky T, Grund JPC, Latypov A, Otiashvili D, Stuikyte R, Scutelniciuc O. (2012) Harm reduction in central and Eastern Europe. In: Pates R, Riley D, editors. Harm reduction in substance use and high-risk behaviour: international policy and practice summaries. Volume 32. 5. Oxford: Wiley Blackwell; 2012. pp. 301–21.

Carlisle Maxwell J. Trends in the abuse of prescription drugs. Austin, Texas: The Gulf Coast Addiction Technology Transfer Center (GCATTC); 2006.

Lankenau SE, Teti M, Silva K, Jackson Bloom J, Harocopos A, Treese M. Initiation into prescription opioid misuse amongst young injection drug users. Int J Drug Policy. 2012;23(1):37–44. doi: 10.1016/j.drugpo.2011.05.014. PubMed DOI PMC

Katz N, Dart RC, Bailey E, Trudeau J, Osgood E, Paillard F. Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse. 2011;37(Suppl. 4):205–17. doi: 10.3109/00952990.2011.569623. PubMed DOI

UNODC . The non-medicinal use of prescription drugs. Policy direction issues. Discussion paper. Vienna: UNODC; 2011.

Fleming GF, McElnay JC, Hughes CM. The separation of codeine from nonprescription combination analgesic products. Subst Use Misuse. 2003;38(Suppl. 9):1217–26. doi: 10.1081/JA-120018480. PubMed DOI

Gordon SM, Forman RF, Siatkowski C. Knowledge and use of the internet as a source of controlled substances. J Subst Abuse Treat. 2006;30(Suppl. 3):271–4. doi: 10.1016/j.jsat.2005.08.013. PubMed DOI

Budman SH, Grimes Serrano JM, Butler SF. Can abuse deterrent formulations make a difference? Expectation and speculation. Harm Reduct J. 2009;6(Suppl. 8):1–7. PubMed PMC

Nielsen S, Barratt MJ. Prescription drug misuse: is technology friend or foe? Drug Alcohol Rev. 2009;28(Suppl. 1):81–6. doi: 10.1111/j.1465-3362.2008.00004.x. PubMed DOI

Raffa RB, Pergolizzi JV. Opioid formulations designed to resist/deter abuse. Drugs. 2010;70(Suppl. 13):1657–75. doi: 10.2165/11537940-000000000-00000. PubMed DOI

Romach MK, Schoedel KA, Sellers EM. Update on tamper resistant drug formulations. Drug Alcohol Depend. 2013;130:13. doi: 10.1016/j.drugalcdep.2012.12.028. PubMed DOI

EMCDDA . The Internet and drug markets. 2015.

Dolliver DS. Evaluating drug trafficking on the Tor Network: Silk Road 2, the sequel. Int J Drug Policy. 2015;26:1113-23. Available online 14 Jan 2015. PubMed

Konrad A. Feds say they’ve arrested ‘dread pirate Roberts,’ shut down his black market ‘the Silk Road’. [http://www.forbes.com/sites/alexkonrad/2013/10/02/feds-shut-down-silk-road-owner-known-as-dread-pirate-roberts-arrested]. Accessed 18 Mar 2015.

Barratt MJ, Ferris JA, Winstock AR. Use of Silk Road, the online drug marketplace, in the United Kingdom, Australia and the United States. Addiction. 2014;109(Suppl. 5):774–83. doi: 10.1111/add.12470. PubMed DOI

Davey Z, Schifano F, Corazza O, Deluca P. e-Psychonauts: conducting research in online drug forum communities. J Ment Health. 2012;21(Suppl. 4):386–94. doi: 10.3109/09638237.2012.682265. PubMed DOI

Forsyth AJM. Virtually a drug scare: mephedrone and the impact of the Internet on drug news transmission. Int J Drug Policy. 2012;23(Suppl. 3):198–209. doi: 10.1016/j.drugpo.2011.12.003. PubMed DOI

Van Hout MC, Bingham T. ‘Surfing the Silk Road’: a study of users’ experiences. Int J Drug Policy. 2013;24(6):524–9. doi: 10.1016/j.drugpo.2013.08.011. PubMed DOI

Van Hout MC, Bingham T. Responsible vendors, intelligent consumers: Silk Road, the online revolution in drug trading. Int J Drug Policy. 2014;25(2):183–9. doi: 10.1016/j.drugpo.2013.10.009. PubMed DOI

Chiauzzi E, DasMahapatra P, Lobo K, Barratt MJ. Participatory research with an online drug forum: a survey of user characteristics, information sharing, and harm reduction views. Subst Use Misuse. 2013;48(Suppl. 8):661–70. doi: 10.3109/10826084.2013.800117. PubMed DOI

Móró L, Rácz J. Online drug user-led harm reduction in Hungary: a review of “Daath”. Harm Reduct J. 2013;10:18. doi: 10.1186/1477-7517-10-18. PubMed DOI PMC

Soussan C, Kjellgren A. Harm reduction and knowledge exchange—a qualitative analysis of drug-related internet discussion forums. Harm Reduct J. 2014;11:25. doi: 10.1186/1477-7517-11-25. PubMed DOI PMC

Soussan C, Kjellgren A. “Chasing the high”—experiences of ethylphenidate as described on international Internet forums. Subst Abuse. 2015;9:9–16. PubMed PMC

Van Hout MC, Hearne E. ‘Word of mouse’: indigenous harm reduction and online consumerism of the synthetic compound methoxphenidine. J Psychoact Drugs. 2014;47(Suppl. 1):30–41. PubMed

EHRN. Young people and injecting drug use in selected countries of Central and Eastern Europe. [http://www.harm-reduction.org/library/young-people-injecting-drug-use-selected-countries-central-andeastern-europe]. Accessed 9 Nov 2013.

Clatts MC, Heimer R, Abdala N, Goldsamt L, Sotheran J, Anderson KT, et al. HIV-1 transmission in injection paraphernalia: heating drug solutions may inactivate HIV-1. J Acquir Immune Defic Syndr. 1999;22(2):194–9. PubMed

Grund JPC, Kaplan CD, Adriaans NFP, Blanken P. Drug sharing and HIV transmission risks: the practice of “frontloading” in the Dutch injecting drug user population. J Psychoact Drugs. 1991;23:1–10. doi: 10.1080/02791072.1991.10472569. PubMed DOI

Dumchev KV, Soldyshev R, Qian HZ, Zezyulin OO, Chandler SD, Slobodyanyuk P, et al. HIV and hepatitis C virus infections among hanka injection drug users in central Ukraine: a cross-sectional survey. Harm Reduction Journal. 2009;6:23. PubMed PMC

Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health. 2001;91(1):42–6. doi: 10.2105/AJPH.91.1.42. PubMed DOI PMC

Binswanger IA, Kral AH, Bluthenthal RN, Rybold DJ, Edlin BR. High prevalence of abscesses and cellulitis among community-recruited injection drug users in San Francisco. Clin Infect Dis. 2000;30:579–81. doi: 10.1086/313703. PubMed DOI

Murphy EL, DeVita D, Liu H, Vittinghoff E, Leung P, Ciccarone DH, et al. Risk factors for skin and soft-tissue abscesses among injection drug users: a case-control study. Clin Infect Dis. 2001;33:35–40. PubMed

Ciccarone D, Bourgois P. Explaining the geographical variation of HIV among injection drug users in the United States. Subst Use Misuse. 2003;38:2049–63. doi: 10.1081/JA-120025125. PubMed DOI PMC

Lloyd-Smith E, Wood E, Zhang R, Tyndall MW, Montaner JS, Kerr T. Risk factors for developing a cutaneous injection-related infection among injection drug users: a cohort study. BMC Pub Health. 2008;8:405. doi: 10.1186/1471-2458-8-405. PubMed DOI PMC

UNAIDS . The GAP report 2014: people who inject drugs. Geneva: UNAIDS; 2014.

Asaeva AV, Ocheret D, Fayziev Zh. Russia: New trends in drug use lead to severe health consequences and death among IDUs: 3-7 April 2011; 22nd international conference on the reduction of drug related harm, Beirut, 2011.

Poghosyan YM, Hakobyan KA, Poghosyan AY, Avetisyan EK. Surgical treatment of jaw osteonecrosis in “Krokodil” drug addicted patients. J Cranio-Maxillo- Fac Surg. 2014;42:1639–43. doi: 10.1016/j.jcms.2014.05.005. PubMed DOI

Orekhovsky V, Calzavara L, Yakovlev A, Nikitina T, Volkova G, Michalchenko M, Saldanha V. Fuelling HIV epidemic in Russia: the stigma of IDU and HIV and its impact on treatment access and testing. In: Poster presentation, The XIV international AIDS conference: 7-12 July, 2002

Elovich R, Drucker E. On drug treatment and social control: Russian narcology’s great leap backwards. Harm Reduct J. 2008;5:23. doi: 10.1186/1477-7517-5-23. PubMed DOI PMC

Wolfe D, Carrieri MP, Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet. 2010;376(Suppl. 9738):355–66. doi: 10.1016/S0140-6736(10)60832-X. PubMed DOI

Couper J. Sur les effets du peroxide de manganèse. Journal de chimie médicale, de pharmacie et de toxicologie. 1873;3:223–5.

Crossgrove J, Zheng W. Manganese toxicity upon overexposure. NMR Biomed. 2004;17:544–53. doi: 10.1002/nbm.931. PubMed DOI PMC

Lucchini RG, Martin CJ, Doney BC. From manganism to manganese-induced parkinsonism: a conceptual model based on the evolution of exposure. Neuromolecular Med. 2009;11(4):311–21. doi: 10.1007/s12017-009-8108-8. PubMed DOI PMC

Sikk K, Haldre S, Aquilonius SM, Taba P. Manganese-induced parkinsonism due to ephedrone abuse. Parkinsons Dis. 2011;4:1-8. PubMed PMC

de Bie RMA, Gladstone RM, Strafella AP, Ko JH, Lang AE. Manganese-induced parkinsonism associated with methcathinone (ephedrone) abuse. Arch Neurol. 2007;64(6):886–9. doi: 10.1001/archneur.64.6.886. PubMed DOI

Lucchini R, Selis L, Folli D, Apostoli P, Mutti A, Vanoni O, Iregren A, Alessio L. Neurobehavioral effects of manganese in workers from a ferroalloy plant after temporary cessation of exposure. Scand J Work Environ Health. 1995;21(Suppl. 2):143–9. doi: 10.5271/sjweh.1369. PubMed DOI

Papanti D, Grund J-P, Francesconi F, Orsolini L, Schifano F. (New) Glocal syndremics: the ‘M-cat’ tale. Res Advances Psychiatry. 2014;1(Suppl. 1):27.

Bluelight. Manganese poisoning from ephedrone (MCAT). [http://bluelight.org/vb/archive/index.php/t-665468.html]. Accessed 6 Apr 2014.

Oldenburg BF, Hardcastle DM, Kok G. Diffusion of innovations. In: Glanz K, Lewis FM, Rimer B, editors. Health behavior and health education: theory, research and practice. 2. San Francisco: Jossey-Bass; 1997. pp. 207–86.

Ferrence R. Diffusion theory and drug use. Addiction. 2001;96(Suppl. 1):165–73. doi: 10.1046/j.1360-0443.2001.96116512.x. PubMed DOI

Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2010;375:1014. PubMed

Pizzey R, Hunt N. Distributing foil from needle and syringe programmes (NSPs) to promote transitions from heroin injecting to chasing: an evaluation. Harm Reduct J. 2008;5:24. doi: 10.1186/1477-7517-5-24. PubMed DOI PMC

Bojko MJ, Dvoriak S, Altice FL. At the crossroads: HIV prevention and treatment for people who inject drugs in Ukraine. Addiction. 2013;108(10):1697–9. doi: 10.1111/add.12243. PubMed DOI PMC

Hedrich D, Kerr T, Dubois-Arber F. Drug consumption facilities in Europe and beyond. In: Rhodes T, Hendrich D, editors. Harm reduction: evidence, impacts and challenges. Luxembourg: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Scientific Monograph, Office of the European Union; 2010.

Alistar SS, Owens DK, Brandeau ML. Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine. PLoS Med. 2011;8 doi: 10.1371/journal.pmed.1000423. PubMed DOI PMC

Different phases of ATS use call for different interventions: a large qualitative study in Europe